Everything below concerns GIP receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
==== Suppression of Cossack autonomy in the Russian Empire ==== Historian Gary Dean Peterson writes: "With all this unrest, Ivan Mazepa of the Ukrainian Cossacks was looking for an opportunity to secure independence from Russia and Poland". In response to Mazepa's alliance with Charles XII of Sweden, Peter I ordered the sacking of the then capital of the Hetmanate, Baturyn. The city was burnt and looted, and 11,000 to 14,000 of its inhabitants were killed. The destruction of the Hetmanate's capital was a signal to Mazepa and the Hetmanate's inhabitants of severe punishment for disloyalty to the Tsar's authority. The Zaporizhian Sich at Chortomlyk, which had existed since 1652, was also destroyed by Peter I's forces in 1709, in retribution for decision of its otaman Kost Hordiyenko, to ally with Mazepa. Under Russian rule, the Cossack nation of the Zaporozhian Host was divided into two autonomous republics of the Russian Tsardom: the Cossack Hetmanate, and the more independent Zaporizhia. These organizations gradually lost their autonomy, and were abolished by Catherine II in the late 18th century. The Hetmanate became the governorship of Little Russia, and Zaporizhia was absorbed into New Russia.
=== Differential diagnoses === The differential diagnoses are extensive and include: Alagille syndrome, alpha-1-antitrypsin deficiency, Byler disease (progressive familial intrahepatic cholestasis), Caroli disease, choledochal cyst, cholestasis, congenital cytomegalovirus disease, congenital herpes simplex virus infection, congenital rubella, congenital syphilis, congenital toxoplasmosis, cystic fibrosis, galactosemia, idiopathic neonatal hepatitis, lipid storage disorders, neonatal hemochromatosis, and total parenteral nutrition-associated cholestasis.
=== Nutritional adjuncts === In the context of managing the adverse effects of chemotherapy, some research has looked at whether omega‑3 supplements might help patients mitigate toxicity and maintain their physical strength. A 2015 review of small studies, alongside more recent 2022 research, found signs that omega‑3s may help patients keep more of their body weight and muscle, support certain aspects of quality of life, and decrease treatment-related toxicity and inflammation. The evidence is still limited and the studies varied, so it is not known how meaningful these effects are. However, reviews note that patients taking omega‑3 supplements alongside conventional therapies do not do worse than those who do not. Similarly, a 2022 meta-analysis and a 2023 systematic review focusing on lung cancer patients undergoing radiotherapy and chemotherapy found that omega-3 supplementation helped improve nutritional status, such as maintaining body weight, and reduced markers of inflammation and treatment toxicity. Additionally, researchers are investigating the molecular mechanisms of omega-3s to see if they might help combat chemoresistance, particularly in breast cancer treatments. Another analysis looking at adults receiving chemotherapy or radiotherapy found that high‑calorie oral nutritional supplements without omega‑3 fats did not help patients maintain their weight, while high‑protein supplements enriched with omega‑3s were linked with better weight maintenance than similar‑calorie products without omega‑3s.
In metallocenes of the type (C5R5)2M, the cyclopentadienyl rings rotate with very low barriers. Single crystal X-ray diffraction studies reveal both eclipsed or staggered rotamers. For non-substituted metallocenes the energy difference between the staggered and eclipsed conformations is only a few kJ/mol. Crystals of ferrocene and osmocene exhibit eclipsed conformations at low temperatures, whereas in the related bis(pentamethylcyclopentadienyl) complexes the rings usually crystallize in a staggered conformation, apparently to minimize steric hindrance between the methyl groups.
=== Chief executives === 1907–1962, James E. "Jim" Casey 1962–1972, George D. Smith 1972–1973, Paul Oberkotter 1973–1980, Harold Oberkotter 1980–1984, George Lamb 1984–1989, John W. Rogers 1989–1996, Kent C. "Oz" Nelson 1997–2001, James P. Kelly 2002–2007, Michael L. "Mike" Eskew 2008–2014, Scott Davis 2014–2020, David Abney 2020–current, Carol B. Tomé
Sources: en.wikipedia.org
=== Mexico === The Secretariat of National Defense issues the "Individual Soldiers Daily Combat Meal" box (Spanish: Ración Diaria Individual de Combate). It is packaged in an olive green and black plastic box with the contents printed on the front; the box contains three individual meal packs containing meals providing 3,640 to 4,030 kcal (15,200 to 16,900 kJ) which are meant to sustain a soldier for one day. Each individual meal package contains two main retort pouches which are meant to be eaten with each other. The first retort pouch usually contains a meat product (such as beef, pork, sausage, fish, ham, seafood, chicken, tuna, bacon, or other meats which are usually mixed with a flavoring sauce and vegetables) the second retort pouch contains a staple food (rice, hominy, noodles, beans, pasta, eggs, or more vegetables). Each meal package also contains salt, spices, condensed milk, cream, butter, chorizo spread, dried fruit or preserves, bread, crackers, sugar, custard, cookies, canned fish, cocoa mix, nuts, chocolate or other candies, vitamins, a large pouch of drinking water, a pouch of Jumex fruit juice or Coca-Cola, biodegradable napkins and utensils, and water purification tablets. Some meal packages do not contain the two main retort pouches and instead contain a single larger pouch with a finished meal such as tamales or steak and eggs but, these are usually only available when close to a base or when the military is operating in an urban area.
It is commonly used in lieu of boric acid and can be used to help control and possibly eliminate bed bugs, house dust mite, cockroach, ant, and flea infestations. Diatomaceous earth is widely applied for insect control in grain storage. It is used to control cannibalistic behaviors in confused flour beetles, which infest flour storages. To be effective as an insecticide, diatomaceous earth must have a mean particle size below about 12 μm (i.e., food grade—see below); and it must be uncalcinated (i.e., it must not be heat-treated prior to application). Although considered to be relatively low-risk, pesticides containing diatomaceous earth are not exempt from regulation in the United States under the Federal Insecticide, Fungicide, and Rodenticide Act and must be registered with the Environmental Protection Agency.
Stimulates the uptake of glucose – Insulin decreases blood glucose concentration by inducing intake of glucose by the cells. This is possible because Insulin causes the insertion of the GLUT4 transporter in the cell membranes of muscle and fat tissues which allows glucose to enter the cell. Increased fat synthesis – insulin forces fat cells to take in blood glucose, which is converted into triglycerides; decrease of insulin causes the reverse. Increased esterification of fatty acids – forces adipose tissue to make neutral fats (i.e., triglycerides) from fatty acids; decrease of insulin causes the reverse. Decreased lipolysis in – forces reduction in conversion of fat cell lipid stores into blood fatty acids and glycerol; decrease of insulin causes the reverse. Induced glycogen synthesis – When glucose levels are high, insulin induces the formation of glycogen by the activation of the hexokinase enzyme, which adds a phosphate group in glucose, thus resulting in a molecule that cannot exit the cell. At the same time, insulin inhibits the enzyme glucose-6-phosphatase, which removes the phosphate group. These two enzymes are key for the formation of glycogen. Also, insulin activates the enzymes phosphofructokinase and glycogen synthase which are responsible for glycogen synthesis.
THIQ is a drug used in scientific research, which is the first non-peptide agonist developed that is selective for the melanocortin receptor subtype MC4. In animal studies, THIQ stimulated sexual activity in rats, but with little effect on appetite or inflammation. This supports possible application of MC4 selective agonists for the treatment of sexual dysfunction in humans, although THIQ itself has poor oral bioavailability and a short duration of action so improved analogues will need to be developed.
A tumour vaccine can stimulate the body's immune system, upon exposure to a tumour-specific peptide antigen, by activation or amplification of a humoral and cytotoxic immune response targeted at the specific cancer cells. The study of Schumacher et al. has been shown that this attractive target (the mutation in the isocitrate dehydrogenase 1) from an immunological perspective represents a potential tumour-specific neoantigen with high uniformity and penetrance and could be exploited by immunotherapy through vaccination. Accordingly, some patients with IDH1-mutated gliomas demonstrated spontaneous peripheral CD4+ T-cell responses against the mutated IDH1 region with generation B-cell producing antibodies. Vaccination of MHC-humanized transgenic mice with mutant IDH1 peptide induced an IFN-γ CD4+ T-helper 1 cell response, indicating an endogenous processing through MHC class II, and production of antibodies targeting mutant IDH1. Tumour vaccination, both prophylactic and therapeutic, resulted in growth suppression of transplanted IDH1-expressing sarcomas in MHC-humanized mice. This in vivo data shows a specific and potent immunologic response in both transplanted and existing tumours.
Sources: en.wikipedia.org
== Uses == The useful buffer range for tris (pH 7–9) coincides with the physiological pH typical of most living organisms. This, and its low cost, make tris one of the most common buffers in the biology/biochemistry laboratory. Tris is also used as a primary standard to standardize acid solutions for chemical analysis. Tris is used to increase permeability of cell membranes. It is a component of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine for use in children 5 through 11 years of age.
It is at this point where the size difference in human vs animal red blood cells can create inaccurate readings. Glucometers for humans were successfully used with pets long before animal-oriented meters were produced. A 2009 study directly compared readings from both types of glucometers to those of a chemistry analyzer. Neither glucometer's readings exactly matched those of the analyzer, but the differences of both were not clinically significant when compared to analyzer results. All glucometer readings need to be compared to same sample laboratory values to determine accuracy. Continuous glucose monitoring Some veterinarians are using continuous monitoring as part of the dog's treatment plan (2019). Sensors intended for humans, e.g. Abbot labs Freestyle Libre, can be applied and provide direct measurement of glucose levels eliminating the need for daily urine or blood checks.
=== Theory of cellular division: S. Rosetta === Work by Fairclough, Dayel and King suggests that S. Rosetta can exist in either single-cellular form or in colonies of 4-50 cells, which arrange themselves in tight knit packs of spheres. This was established by performing an experiment involving the introduction of prey bacterium Algoriphagus species to a sample of uni-celled S. Rosetta organism and monitored the activity for 12 hours. Results of this study demonstrated that cell colonies were formed through cell-division of the initial solitary S. Rosetta cell rather than by cell aggregation. Further studies to support the theory of cell-proliferation were done by introducing then removing the drug aphidicolin which serves to block cell-division. When the drug was introduced, cell division stopped and colony formation resulted through cell-cell aggregation. When the drug was removed, cell-division dominated once again.
== Evolved adaptations == The human penis has been argued to have several evolutionary adaptations that maximise reproductive success and minimise sperm competition. Sperm competition is where the sperm of two males simultaneously occupy the reproductive tract of a female and they compete to fertilise the egg. If sperm competition results in the rival male's sperm fertilising the egg, cuckoldry could occur. This is the process whereby males unwittingly invest their resources into offspring of another male and, evolutionarily speaking, should be avoided. The most researched human penis adaptations are penis size and semen displacement.
MetaPred: A webserver for the prediction of cytochrome P450 isoforms responsible for metabolizing a drug molecule. The MetaPred server predicts metabolizing CYP isoforms of a drug molecule/substrate based on SVM models developed using CDK descriptors. This server is intended to help researchers working in the field of drug discovery. The effort also demonstrates that it is possible to develop free web servers in the field of cheminformatics. This may encourage other researchers to develop web servers for public use, leading to decreased cost of discovering new drug molecules. ToxiPred: A server for prediction of aqueous toxicity of small chemical molecules in T. pyriformis. KetoDrug: A user friendly web server for binding affinity prediction of ketoxazole derivatives and small chemical molecules against Fatty Acid Amide Hydrolase (FAAH). KiDoQ: A web server to serve researchers working in the field of designing inhibitors against dihydrodipicolinate synthase (DHDPS), a potential drug target enzyme of a unique bacterial DAP/Lysine pathway. GDoQ: GDoQ (Prediction of GLMU inhibitors using QSAR and AutoDock) is an open source platform for predicting inhibitors against Mycobacterium tuberculosis (M.Tb) drug target N-acetylglucosamine-1-phosphate uridyltransferase (GLMU) protein. This is a potential drug target involved in bacterial cell wall synthesis. This server uses molecular docking and QSAR strategies to predict inhibitory activity value (IC50) of chemical compounds for GLMU protein. ROCR: The ROCR is an R package for evaluating and visualizing classifier performance.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.